This webinar will look at clinical and imaging biomarkers in Parkinsonian syndromes to provide trial sponsors a rounded overview of key challenges and considerations.
Parkinsonian syndromes can be challenging to diagnose, with significant clinical overlap between the disorders. This webinar aims to give a clinical overview of the presentation of these disorders and discuss the important clinical features that aid correct diagnosis. It will also address the diagnostic challenges faced when recruiting for clinical trials and when the use of imaging, in particular MRI, can be useful in differential diagnosis of Parkinsonism.
The second part of the webinar will review the role of traditional imaging biomarkers in Parkinson’s disease clinical trials. For example, the use of dopamine transporter (DAT) neuroimaging, which remains a useful technique at the early stages of clinical trials and was issued a formal qualification opinion by the EMA in 2018 as an enrichment biomarker for clinical trials.
Register for this webinar to hear about the aforementioned topics, as well as interest in the use of neuroimaging biomarkers to measure disease progression in Parkinson’s disease. Longitudinal studies have reported the use of a combination of imaging modalities, and there has been more interest in recent years in the use of advanced MRI techniques, some of which include: neuromelanin, iron and diffusion imaging, with early results suggesting there may be a role for these techniques as potential imaging biomarkers to measure disease progression.
Horacio Kaufmann, MD, Professor, Department of Neurology, Medicine, and Pediatrics, NYU Langone Health. Director, Division of Autonomic Disorders (Neurology) NYU Grossman School of Medicine
Dr. Horacio Kaufmann is Professor of Neurology, Medicine and Pediatrics and holds the F.B. Axelrod Chair for Neurological Research at New York University School of Medicine where he also heads the division of Autonomic Disorders and the Dysautonomia Center at NYU Langone Health. Dr. Kaufmann received his medical degree from the National University of Buenos Aires, Argentina. He trained in Internal Medicine and completed Neurology residency and fellowship at Mount Sinai School of Medicine in New York City.
Dr. Kaufmann is one of the world’s foremost experts and a leader in the field of autonomic disorders including Parkinson’s disease and multiple system atrophy. His research focuses on the autonomic nervous system and its abnormalities in neurological disorders, and he has conducted innovative clinical trials of the main drugs used in the treatment of these disorders.Message Presenter
Hiba Kazmi, PhD, Associate Biomarker Scientist, IXICO
Dr. Hiba Kazmi graduated from King’s College London with a Master’s degree in Clinical Neuroscience and holds a PhD from University College London (UCL) Queen Square Institute of Neurology. Her PhD investigated the presence of clinical and imaging features associated with prodromal Parkinson’s Disease in patients with late onset depression. She also has experience in clinical settings, including working with patients with psychiatric disorders such as depression and schizophrenia.
Hiba currently works at IXICO as an Associate Biomarker Scientist, across a range of therapeutic areas including Parkinson’s disease, Progressive Supranuclear Palsy and Alzheimer’s disease.Message Presenter
Who Should Attend?
- Chief Medical/Scientific Officer
- Heads of: R&D, Clinical Research, Clinical Development, Clinical Operations
- TA Head/Lead
- Clinical Lead
- Medical Monitors
- Clinical Scientists
- Imaging Scientist
- Biomarkers Scientists
- Study/Project Manager
- Clinical OperationsDirector/Manager
- Protocol Manager
- Study Startup
What You Will Learn
The panellists will focus on the following topics:
- A clinical overview of parkinsonian syndromes with a focus on Parkinson’s disease (PD), multiple systems atrophy (MSA) and progressive supranuclear palsy (PSP)
- Addressing diagnostic challenges when recruiting for clinical trials
- Overview of the use of current imaging biomarkers in clinical trials in Parkinson’s disease
- Introduction to emerging imaging biomarkers in Parkinson’s disease
IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together breakthrough AI innovations, deep neuroscience expertise and operational excellence, IXICO enables clients to realize the full power of neuroimaging in CNS clinical trials.
With specialist CNS knowledge, access to highly curated neurological patient data and proven pipeline algorithms to measure brain biomarkers, we help sponsors directly answer their research questions relating to disease symptoms, delivery mechanism, mode of action, drug safety and efficacy. Our advanced neuroimaging and analytics solutions unlock clinically meaningful insights across the entire development lifecycle, from Phase I through to commercialization. Supporting clients to make better informed decisions earlier in the development pathway, IXICO helps accelerate R&D decision making, de-risk clinical research and optimize pipeline investments.